Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Botulism Antitoxin Heptavalent Types A-G

Plasma-derived product · Acts on botulinum toxin type A, botulinum toxin type B and botulinum toxin type C · developed by Emergent BioSolutions

Phase 1 Most advanced trial (none active)

EBS Developer

1 Registered trials

What is Botulism Antitoxin Heptavalent Types A-G?

Botulism Antitoxin Heptavalent Types A-G is a plasma-derived antitoxin containing antibodies against botulinum toxins types A through G. It neutralizes circulating botulinum toxins to treat or prevent botulism.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Plasma-derived product
Targets: botulinum toxin type A, botulinum toxin type B, botulinum toxin type C, botulinum toxin type D, botulinum toxin type E, botulinum toxin type F
Mechanism: Acts on botulinum toxin type A, botulinum toxin type B and botulinum toxin type C
Therapy area: Infectious disease
Developer: Emergent BioSolutions (EBS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT00636519	Phase 1	Healthy Volunteers	Completed	EBS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteers

More from Emergent BioSolutions

AIGIV FDA approved Bacillus anthracis strain V770-NP1-R antigens FDA approved Brincidofovir FDA approved smallpox vaccine live, New York City Board of Health vaccinia strain FDA approved Vaccinia Immune Globulin FDA approved Ad4-EnvC150 Phase 1 Ad4-H5-Vtn Phase 1 Ad4-mgag Phase 1 Ad4-PA-1 Phase 1 Ad4-PA-GPI-1 Phase 1 AIDSVAX B/E Phase 1 AV7909 Phase 3

Sources

ClinicalTrials.gov NCT00636519

Updated Oct 3, 2026. Something wrong or missing? Report it on the EBS page.

Follow EBS, the company behind Botulism Antitoxin Heptavalent Types A-G

See EBS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

EBS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z